Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer
NCT07755436Phase 1Recruiting
- Sponsor
- ArriVent BioPharma
- Start
- Jul 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ARR-002 in ovarian cancer and endometrial cancer (EC), sponsored by ArriVent BioPharma. Primary endpoints: Treatment-Emergent Adverse Event and Maximum Tolerated Dose. Started Jul 2026; status: recruiting.
02
Drugs
ARR-002
03
Conditions
ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT07755436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07755436.